science

List of investigational eating disorder drugs

List of investigational eating disorder drugs is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand List of investigational eating disorder drugs rather than just read about it. In short: This is a list of investigational eating disorder drugs, or drugs that are currently under development for clinical use for the treatment of eating disorders but are not yet approved. Eating disorders include anorexia nervosa, bulimia nervosa, and binge-eating disorder, among others.

Key takeaways

List of investigational eating disorder drugs belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect List of investigational eating disorder drugs to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of List of investigational eating disorder drugs from memory before moving on to harder problems.

Reference excerpt

This is a list of investigational eating disorder drugs, or drugs that are currently under development for clinical use for the treatment of eating disorders but are not yet approved. Eating disorders include anorexia nervosa, bulimia nervosa, and binge-eating disorder, among others. This page does not include drugs under development for treatment of overweightness/obesity (excessive appetite) or anorexia (low appetite). Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". This list was last comprehensively updated in January 2026. It is likely to become outdated with time.

Under development

Phase 3 Armodafinil ((R)-modafinil; CEP-10953; Nuvigil) – atypical dopamine reuptake inhibitor (DRI) – eating disorders [1] Solriamfetol (ADX-N05; ARL-N05; JZP-110; SKL-N05; Sunosi) – norepinephrine–dopamine reuptake inhibitor (NDRI) – binge-eating disorder [2]

Phase 2 BP-14979 (BP-1.4979; BP1-4979) – dopamine D3 receptor partial agonist – binge-eating disorder [3] Lidocaine (ORE-001) – sodium channel blocker – anorexia nervosa [4] Naloxone nasal spray (LT-12; LT-20; LT-21; LT-22; Naloxon B; Narcan nasal spray; OPNT-001) – μ-opioid receptor antagonist – eating disorders [5] Nivasorexant (ACT-539313; SORA) – orexin OX1 receptor antagonist – binge-eating disorder [6] Oxytocin (intranasal potentiated oxytocin; TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist – binge-eating disorder [7] Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – anorexia nervosa [8] Psilocybin (PFN™; TRP-8802; TRP-8803; TRP-8804; TRYP-0082) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – binge-eating disorder [9] Vortioxetine (Brintellix; LU-AA21004; LuAA 21004; Trintellix; Vortidif) – serotonin reuptake inhibitor, serotonin 5-HT1A and 5-HT1B receptor agonist, and serotonin 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist – binge-eating disorder [10]

Phase 1 CVN-766 (CVN766) – orexin OX1 receptor antagonist – binge-eating disorder [11]

Preclinical Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – eating disorders [12] TACT411 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – anorexia nervosa, binge-eating disorder TACT523 – undefined mechanism of action – anorexia nervosa, binge-eating disorder TACT833 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – anorexia nervosa, binge-eating disorder

Not under development

No development reported BMB-101 (BMB101) – serotonin 5-HT2C receptor agonist – binge-eating disorder [13] GSK-598809 (GSK598809) – dopamine D3 receptor antagonist – eating disorders [14] Ibogaine – various actions – anorexia nervosa Ketamine (AWKN-001; AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – binge-eating disorder [15] Mescaline (BMND-04/BMND04) – non-selective serotonin receptor agonist and psychedelic hallucinogen – eating disorders Olanzapine (BR-5402; LY-170053; LY-170052; Midax; Zypadhera; Zyprexa) – atypical antipsychotic (non-selective monoamine receptor modulator) – anorexia nervosa [16] Psilocybin (PSY-0.1, PSY-0.2, PSY-0.3, PSY-0.4/0.5, PSY-0.6) – non-selective serotonin receptor agonist and psychedelic hallucinogen – eating disorders

Discontinued Amphetamine modified release (HLD-900; HLD-100) – norepinephrine–dopamine releasing agent (NDRA) – bulimia nervosa [17] Centanafadine (CTN-SR; EB-1020) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – binge-eating disorder [18] Dasotraline (DSP-225289; SEP-225289; SEP-0225289; SEP-289) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – binge-eating disorder [19] Femoxetine (femoxitine; FG-4963; Malexil; NNC-204963) – selective serotonin reuptake inhibitor (SSRI) – eating disorders [20] Ghrelin synthetic (OXE-103; SUN-11031) – ghrelin receptor agonist – anorexia nervosa [21] GW-181771 (GI-181771; GSKI-181771X) – cholecystokinin CCKA receptor agonist – bulimia nervosa [22] Meclinertant (reminertant; SR-48692) – neurotensin NTS1 receptor antagonist – anorexia nervosa [23] Naloxone nasal spray (LT-12; LT-20; LT-21; LT-22; Naloxon B; Narcan nasal spray; OPNT-001) – μ-opioid receptor antagonist – bulimia nervosa [24] Samidorphan (ALKS-33; RDC-0313; RDC-0313-00) – μ-opioid receptor antagonist – eating disorders [25] Sertraline (Aremis; Besitran; CP-51974; CP-51974-01; Gladem; J Zoloft; Lustral; Serad; Serlain; Tatig; Zoloft) – selective serotonin reuptake inhibitor (SSRI) – night eating syndrome [26] Tandospirone (metanopirone; Sediel; SM-3997) – serotonin 5-HT1A receptor agonist – eating disorders [27] Ticalopride ((+)-norcisapride) – serotonin 5-HT3 receptor antagonist, serotonin 5-HT4 receptor agonist – bulimia nervosa [28] [29]

Clinically used drugs

Approved drugs Dronabinol (tetrahydrocannabinol; THC; Δ9-THC; Deltanyne; Elevat; Marinol; NSC-134454) – cannabinoid CB1 and CB2 receptor agonist – anorexia nervosa [30] Fluoxetine (LY-110140; Prozac; Reneuron; Sarafem) – selective serotonin reuptake inhibitor (SSRI) – bulimia nervosa [31] Fluoxetine – selective serotonin reuptake inhibitor (SSRI) – bulimia nervosa [32] Lisdexamfetamine (LDX; Elvanse; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – eating disorders [33]

Worked examples

Example 1 — a first encounter with List of investigational eating disorder drugs

Start with the simplest possible case. Write down what List of investigational eating disorder drugs claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to List of investigational eating disorder drugs before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about List of investigational eating disorder drugs ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of List of investigational eating disorder drugs

In research: List of investigational eating disorder drugs appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses List of investigational eating disorder drugs in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: List of investigational eating disorder drugs is common in secondary-school and first-year university syllabi. It links to neighbouring topics Lists of investigational drugs, so understanding it makes those chapters shorter.
In everyday life: Look for List of investigational eating disorder drugs outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “List of investigational eating disorder drugs” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study List of investigational eating disorder drugs in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what List of investigational eating disorder drugs means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain List of investigational eating disorder drugs out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is List of investigational eating disorder drugs in simple terms?

Why does List of investigational eating disorder drugs matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study List of investigational eating disorder drugs?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on List of investigational eating disorder drugs.